Media Coverage · July 31, 2018
Acticor Biotech signe en Chine un contrat de licence de plus de 60 M EUR – AFP [FR]
July 2018. Paris, 31 juil 2018 (AFP) -La société française Acticor Biotech a annoncé mardi la signature avec le groupe pharmaceutique chinois China Medical System (CMS) d’un contrat de transfert d’actifs, de licence et de co-développement concernant son candidat-médicament phare, pour un total dépassant 60 millions d’euros.
Download full text article (PDF, French)
Read next in 'Media Coverage'
- Novel antiplatelet could circumvent bleeding risk for stroke patients
- Experimental antiplatelet compound for acute stroke shows promise
- New drug to prevent clots clears safety hurdle
- New blood thinner may prevent stroke, without risk for bleeding
- Acticor's blood thinner cuts hemorrhage risk in human study, could offer hope for acute stroke